Current treatment strategy and new agents in mantle cell lymphoma
スポンサーリンク
概要
- 論文の詳細を見る
- 2010-07-15
著者
-
OGURA Michinori
Department of Hematology and Cell Therapy, Aichi Cancer Center
-
Ogura Michinori
Department Of Hematology And Oncology Nagoya Daini Red Cross Hospital
-
Ogura Michinori
Department Of Hematology And Cell Therapy Aichi Cancer Center
関連論文
- Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
- Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan
- Durable Response but Prolonged Cytopenia after Cladribine Treatment in Relapsed Patients with Indolent non-Hodgkin's Lymphomas : Results of a Japanese Phase II Study
- Japanese phase II study of ^Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma
- Phase I Trial of FLAGM with High Doses of Cytosine Arabinoside for Relapsed, Refractory Acute Myeloid Leukemia : Study of the Japan Adult Leukemia Study Group (JALSG)
- Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
- Primary Hepatic Follicular Lymphoma : A Case Report and Discussion of Chemotherapy and Favorable Outcomes
- Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma
- Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese
- CD56/NCAM-Positive Langerhans Cell Sarcoma : A Clinicopathologic Study of 4 Cases
- Phenotypic analysis of peripheral T/NK cell lymphoma : Study of 408 Japanese cases with special reference to their anatomical sites
- Pilot Phase I/II Study of New Salvage Therapy(CHASE) for Refractory or Relapsed Malignant Lymphoma
- Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia : Results of a Japanese Phase II Clinical Study
- CD34^+-Selected Autologous Peripheral Blood Stem Cell Transplantation Conditioned With Total Body Irradiation for Malignant Lymphoma: Increased Risk of Infectious Complications
- Assessment of Prognostic Factors in Follicular Lymphoma Patients
- A high dose chemoradiotherapy and peripheral blood stem cell support combined with the CD34^+-selection method in cyclin D1^+-mantle cell lymphoma
- Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study
- NAD(P)H : quinone oxidoreductase 1 (NQ01) C609T polymorphism and the risk of eight cancers for Japanese
- Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab
- Cytotoxic large T-cell lymphoma with fulminant clinical course,CD8^+ and CD56^-phenotype, and its relation to Epstein-Barr virus:a report of two cases
- Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese
- Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
- Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
- Current treatment strategy and new agents in mantle cell lymphoma
- Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma
- Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
- Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
- Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine : a multicenter study
- Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab : A multicenter phase II study
- Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
- Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-and low-intermediate risk, aggressive non-Hodgkin's lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG95
- Stable renal engraftment in a patient following successful tandem artologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del(17p) that developed as a post-transplantation lymphoprpliferative disease fol